Sobi acquires emapalumab and related assets from Novimmune
Swedish Orphan Biovitrum (Sobi) has signed an agreement to acquire, from Novimmune’s shareholders, a newly established company owning emapalumab and related assets. It has also announced a reorganization to increase the focus of research & development resources to support its two core therapeutic areas: Haematology and Immunology. The acquisition gives Sobi access to world-class R&D capabilities … Continue reading Sobi acquires emapalumab and related assets from Novimmune
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed